Amarin (NASDAQ:AMRN) was upgraded by equities research analysts at TheStreet from a “d” rating to a “c-” rating in a research report issued to clients and investors on Friday, TheStreetRatingsTable reports.
Several other analysts also recently issued reports on AMRN. ValuEngine downgraded shares of Amarin from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Stifel Nicolaus reissued a “buy” rating on shares of Amarin in a research note on Tuesday, November 12th. Leerink Swann boosted their target price on shares of Amarin from $28.00 to $29.00 in a research note on Friday. BidaskClub raised shares of Amarin from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Finally, Svb Leerink boosted their target price on shares of Amarin from $26.00 to $29.00 and gave the company an “outperform” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Amarin has an average rating of “Buy” and a consensus price target of $28.91.
Shares of NASDAQ AMRN traded up $0.06 during trading on Friday, hitting $22.66. The company had a trading volume of 424,210 shares, compared to its average volume of 11,206,070. The company has a market cap of $8.58 billion, a P/E ratio of -57.87 and a beta of 1.14. Amarin has a 52 week low of $11.78 and a 52 week high of $24.67. The business’s 50-day moving average is $16.86 and its 200 day moving average is $17.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.45 and a current ratio of 3.69.
Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The company had revenue of $112.40 million for the quarter, compared to analysts’ expectations of $110.04 million. Amarin had a negative return on equity of 26.67% and a negative net margin of 17.42%. The firm’s revenue was up 104.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.08) earnings per share. On average, research analysts expect that Amarin will post -0.13 EPS for the current year.
In other news, Director Lars Ekman sold 38,600 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $24.02, for a total transaction of $927,172.00. Also, CEO John F. Thero sold 475,546 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $24.02, for a total transaction of $11,422,614.92. Over the last 90 days, insiders have sold 605,162 shares of company stock worth $13,715,937. 2.75% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Rational Advisors LLC boosted its holdings in Amarin by 24.0% in the third quarter. Rational Advisors LLC now owns 160,200 shares of the biopharmaceutical company’s stock worth $2,429,000 after purchasing an additional 31,000 shares in the last quarter. Catalyst Capital Advisors LLC raised its position in shares of Amarin by 21.9% during the third quarter. Catalyst Capital Advisors LLC now owns 284,000 shares of the biopharmaceutical company’s stock valued at $4,305,000 after buying an additional 51,000 shares during the last quarter. Morse Asset Management Inc raised its position in shares of Amarin by 146.6% during the third quarter. Morse Asset Management Inc now owns 97,790 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 58,140 shares during the last quarter. Hayek Kallen Investment Management acquired a new position in Amarin in the third quarter worth about $528,000. Finally, Mcclain Value Management LLC raised its position in Amarin by 96.6% in the third quarter. Mcclain Value Management LLC now owns 46,065 shares of the biopharmaceutical company’s stock worth $698,000 after purchasing an additional 22,634 shares in the last quarter. Hedge funds and other institutional investors own 49.61% of the company’s stock.
Amarin Company Profile
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Read More: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.